AZ LICENSES ZURAMPIC TO GRÜNENTHAL GMBH
June 02, 2016 02:00 ET | AstraZeneca PLC
ASTRAZENECA LICENSES ZURAMPIC TO GRÜNENTHAL GMBH IN EUROPE AND LATIN AMERICA Agreement includes rights to the fixed-dose combination of lesinurad and allopurinol in gout AstraZeneca today...
POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA
May 27, 2016 07:53 ET | AstraZeneca PLC
POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR ADULTS WITH TYPE-2 DIABETES AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of...
ASTRAZENECA'S FASLODEX MET PRIMARY ENDPOINT IN FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER
May 27, 2016 02:03 ET | AstraZeneca PLC
AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic...
ASTRAZENECA RECEIVES COMPLETE RESPONSE LETTER FROM US FDA FOR SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) FOR ORAL SUSPENSION FOR TREATMENT OF HYPERKALAEMIA
May 27, 2016 02:00 ET | AstraZeneca PLC
27 May 2016 AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium...
Director/PDMR Shareholding
May 23, 2016 11:00 ET | AstraZeneca PLC
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 23 May 2016, the interest of Luke Miels, a person discharging managerial responsibilities, in AstraZeneca...
TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL
May 18, 2016 02:00 ET | AstraZeneca PLC
ASTRAZENECA PROVIDES TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL IN ADVANCED GASTRIC CANCER 18 May 2016 AstraZeneca today announced that Lynparza (olaparib) in combination with paclitaxel...
POSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA
May 17, 2016 02:00 ET | AstraZeneca PLC
ASTRAZENECA ANNOUNCES POSITIVE RESULTS FROM BENRALIZUMAB PHASE III PROGRAMME IN SEVERE ASTHMA Benralizumab first AstraZeneca respiratory biologic to complete Phase III 17 May 2016 AstraZeneca today...
SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US
May 12, 2016 02:00 ET | AstraZeneca PLC
SELUMETINIB granted Orphan Drug Designation in the US for ADJUVANT treatment of Differentiated thyroid cancer AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted...
Publication of Final Terms
May 11, 2016 10:30 ET | AstraZeneca PLC
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Publication of Final Terms in relation to the...
Launch and pricing of EUR2.2bn bond issues
May 09, 2016 12:52 ET | AstraZeneca PLC
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION AstraZeneca launches and prices bond issues of...